First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease

被引：0

作者：

Marron, T. ^{[1
]}

Rosen, S. ^{[2
]}

Orr, D. ^{[3
]}

Powderly, J., II ^{[4
]}

Khaskhely, N. ^{[5
]}

Bonham, L. ^{[6
]}

Nelson, M. ^{[7
]}

Taromino, C. ^{[8
]}

Taylor, D. ^{[9
]}

Kumer, J. ^{[10
]}

Ellmark, P. ^{[11
]}

Fritzell, S. ^{[12
]}

Ambarkhane, S. V. ^{[13
]}

Huebner, D. ^{[14
]}

Alahmadi, A. ^{[15
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dept Hematol Oncol, New York, NY USA

[2] Hematol Oncol Associates Treasure Coast, Hematol Oncol, Ft Pierce, FL USA

[3] Mary Crowley Canc Res Ctr, Med Oncol, Dallas, TX USA

[4] Carolina BioOncol Inst, Med Oncol, Huntersville, NC USA

[5] Aptevo Therapeut, Clin Affairs, Seattle, WA USA

[6] Aptevo Therapeut, Translat Pharmacol, Seattle, WA USA

[7] Aptevo Therapeut, Immunobiol, Seattle, WA USA

[8] Aptevo Therapeut, Clin Operat, Seattle, WA USA

[9] Aptevo Therapeut, Finance, Seattle, WA USA

[10] Aptevo Therapeut, Proc Adm, Seattle, WA USA

[11] Alligator Biosci AB, Lund, Sweden

[12] Alligator Biosci AB, Clin Affairs, Lund, Sweden

[13] Alligator Biosci AB, Med Clin Res & Dev, Lund, Sweden

[14] Aptevo Therapeut, Seattle, WA USA

[15] OSUCCC Ohio State Univ Comprehens Canc Ctr James, Oncol Dept, Columbus, OH USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.734

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

668P

引用

页码：S524 / S525

页数：2

共 24 条

[1] ALG.APV-527: A 5T4 TUMOR DIRECTED BISPECIFIC APPROACH UTILIZING ADAPTIRTM TECHNOLOGY DESIGNED FOR CONDITIONAL 4-1BB T CELL/NK AGONISM AGAINST SOLID TUMORS
Nelson, Michelle
Sundstedt, Anette
de Coana, Yago Pico
Lucas, Ashly
Nilsson, Anneli
Ljung, Lill
Chunyk, Allison
Schultz, Lena
McMahan, Catherine
Gross, Jane
Frizell, Sara
Ramos, Hilario
Ellmark, Peter
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A831 - A831
[2] First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Ku, G.
Shen, L.
Klempner, S. J.
Pan, H.
Kratz, J.
Liang, X.
Deng, Y.
Kim, S.
Wang, Z.
Feller, L.
Powderly, J.
Dayyani, F.
Schneider, R. E.
Girda, E.
Berlin, J. D.
Spencer, K.
Nguyen, M. T.
Wang, V.
Xu, C.
Zhu, A.
ANNALS OF ONCOLOGY, 2023, 34 : S631 - S631
[3] A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
Xue, J.
Sun, Y.
Li, D.
Guo, Y.
ANNALS OF ONCOLOGY, 2023, 34 : S629 - S629
[4] ATOR-1017, A 4-1BB ANTIBODY, DEMONSTRATES PROMISING SAFETY AND PROOF OF MECHANISM IN A FIRST-IN-HUMAN STUDY IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Carneiro, Ana
Ambarkhane, Sumeet
Smith, Karin Enel
Ullenhag, Gustav
Schulz, Lena
Landstrom, Tova
Ellmark, Peter
Carlsson, Malin
Yachnin, Jeffrey
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A747 - A747
[5] First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.
Guo, Ye
Wu, Lihua
Li, Yong
Wen, Jinhua
Xue, Junli
Wang, Zhuoyi
Li, Pu
Zhao, Wei
Liu, Jingfeng
Rao, Xi
Li, Qun
Xue, Liqiong
Ge, Xiaoxiao
Lin, Fengjuan
Tang, Wenbo
Zhou, Jiuli
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors.
Shapiro, Geoffrey
LoRusso, Patricia
Vaishampayan, Ulka N.
Kittaneh, Muaiad
Hilton, John Frederick
Cleary, James M.
Velastegui, Karen
Xuan, Dawei
Hua, Steven
Shazer, Ronald L.
Borghaei, Hossein
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[7] First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors
Desai, Jayesh
Frentzas, Sophia
Fakih, Marwan
Ameratunga, Malaka
O'Neill, Siobhan
Pelster, Meredith
Stein, Brian N.
Body, Amy
Li, Bai
Strauss, Ross M.
Zhao, Yating
Dong, Gaohong
Cecchini, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 123 - 123
[8] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
Lin, Tongyu
Liu, Bin
Pu, Xingxiang
Wu, Lin
Du, Xiaobo
Mo, Ning
Song, Zhengbo
Zhou, Liwei
Duan, Xianlin
Zhu, Yanan
Kang, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Carneiro, Ana
Hahn, Amanda
Ellmark, Peter
Enell Smith, Karin
Schultz, Lena
Ambarkhane, Sumeet
Yachnin, Jeffrey
Ullenhag, Gustav J.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
[10] First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors
Daud, Adil
Albany, Costantine
Velcheti, Vamsidhar
Hauke, Ralph J.
Ahnert, Jordi Rodon
Karp, Daniel D.
Tsimberidou, Apostolia Maria
Cohen, Julia Wanda
Schmidt, Emmett V.
Wang, Jieyi
Chan, C. Hubert
Fu, Siqing
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 →